Coulter Partners

About Us

We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that change the world. Operating uniquely as one global team, we have honed our expertise, platform, and data for over two decades, working across three continents, and in 40 countries. Applying what we learn through our work with boards, leadership teams, and investors in the world’s most innovative companies, we bring together and develop the right people at the right time to propel them to achieve their worthwhile goals.

Achievements

Recent Placements

Coulter Partners

Find a Recruiter

0

The Coulter Partners team is made up of 110 experts, working in 40 countries, holding 250,000 conversations with industry leaders each year. Together we channel data and learning to the benefit of our clients. We are a diverse group of experts with backgrounds ranging from science and technology, to the arts, finance, and more. Our reward system is designed to drive one-team behaviors and we work together seamlessly to combine industry experience and global insight with our passion for progress. Our team understands and is up to date with the challenges you face and the opportunities your business can maximize. This means we can find and develop exceptional individuals to drive you forward.

Our Team

Coulter Partners

Solutions And Expertise

Our network is carefully curated and gives us access to leaders who can guide science, technology and innovation-driven companies through all stages of growth and evolution. Our executive search is an end-to-end process, underpinned by rigorous data and analytics from our dedicated Business Intelligence function and CP:Net™, our proprietary AI-driven candidate and company database.  Our Board Advisory brings over two decades’ experience in building, advising and evolving boards for private and public companies. We understand what value a board can bring and how to evaluate its suitability for the stage of the business and the 3–5-year plan. We also provide leadership advisory at every step of the way. We have a network of mentors and advisors that bring the next level of insight to your organization, to build teams that change the world.

Solutions
  • Advisory Services
  • Assessment
  • Board Services
  • Culture Shaping
  • Data Analy./Mrkt. Intell.
  • Diversity & Inclusion
  • Executive Coaching
  • Executive Search
  • Leadership Consulting
  • Leadership Develop.
  • Mgmt. Consulting
  • Onboarding
  • Recruitment Research
  • Succession Planning
Industries
  • Agriculture
  • Biotechnology
  • Chemicals
  • Clean Tech./Sustain.
  • Clinical Research
  • Consulting
  • Consumer
  • Consumer Products
  • Consumer Services
  • Data & Analytics
  • Devices
  • Energy
  • Family Offices
  • Financial Services
  • FinTech
  • Foundations
  • Healthcare Services
  • High Tech
  • Industrial
  • Industrial Products
  • Internet
  • Life Sci./Healthcare
  • Machine Learning
  • Medical
  • Medical Devices
  • Natural Resources
  • Non-Profit
  • Pharmaceuticals
  • Private Equity
  • Professional Services
  • Software
  • Supply Chain
  • Technology
  • Venture Capital
Functions
  • Board/Governance
  • Business Development
  • CEO/President
  • Data/Analytics
  • Diversity & Inclusion
  • Finance/Accounting
  • General Management
  • GM/Operations
  • Human Resources
  • Information/Digital
  • Investor Relations
  • Legal/Compliance
  • Manufacturing
  • Marketing & Sales
  • Medical/Clinical
  • Research & Develop.
  • Supply Chain

Coulter Partners

News Briefings

Coulter Partners Recruits Chief Data and Technology Officer for Clinical Partners

Life sciences recruiting specialist Coulter Partners has assisted in the recruitment of Luis De Miguel Puig as chief data and technology officer of Clinical Partners. “Coulter Partners truly understood our requirements for a leader who could champion automation, self-service, and data-driven strategy,” said Barny Guthrie, CEO at Clinical Partners. “They delivered an impressive, diverse shortlist in under 30 days,

Coulter Partners Recruits Chief Scientific Officer for ExpressionEdits

Life sciences recruiting specialist Coulter Partners has helped to recruit Amrik Basran as chief scientific officer of ExpressionEdits. “Amrik’s extensive experience in biologics development makes him an invaluable addition to ExpressionEdits,” said Kärt Tomberg, co-founder and CEO of ExpressionEdits. “His leadership will be key as we expand from platform innovation to therapeutic development, ensuring our technology

Coulter Partners Recruits Chief Medical Officer for Bausch Health

Life sciences recruiting specialist Coulter Partners has assisted in the recruitment of Jonathan Sadeh as executive vice president, chief medical officer and head of R&D at NYSE-traded Bausch Health Companies Inc. Antonietta Baffa, Lilyana Chukova, and Nona Footz led the assignment. “We are delighted to welcome Jonathan as our new head of research and development,” said Thomas J. Appio,

Coulter Partners Assists NeoPhore with CEO Search

Life sciences recruiting specialist Coulter Partners has assisted in the recruitment of Michael Shih as the new CEO of NeoPhore in London. Leading the assignment were Chris Palatucci, Clare Evans-Argent, Gabrielle Banzon, and Kay Wardle. The appointment follows the close of the company’s oversubscribed series B financing. The financing and new appointment of the CEO strengthen NeoPhore’s

Coulter Partners

Press Releases

Coulter Partners places Daniel Green as Chief Operating Officer at mOm Incubators

Coulter Partners successfully led a search assignment for mOm Incubators Ltd (“mOm”) and is pleased to announce the placement of Daniel Green as Chief Operating Officer (COO). mOm is a pioneering UK-based health-tech company dedicated to transforming neonatal care. Its flagship product, the mOm Essential Incubator, is a world-first, lightweight, and portable device designed to maintain

Coulter Partners successfully led a search assignment for Trevi Therapeutics, Inc. (Nasdaq: TRVI) and is pleased to announce the placement of David Hastings as Chief Financial Officer (CFO)

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). David Hastings brings over 25 years of financial leadership in the public life sciences and biopharmaceutical

Coulter Partners places Chief Executive Officer at Alethio Therapeutics

Coulter Partners successfully completed a search assignment for Alethio Therapeutics – formerly known as Alethiomics – and is pleased to announce the placement of Dr. Rohit Batta as Chief Executive Officer. Alethio Therapeutics is a biotech company advancing therapies designed to help people with Myeloproliferative Neoplasms (MPNs) live longer, healthier, and more fulfilling lives. Backed by

Coulter Partners continues strategic reorganization to drive global growth and innovation

Coulter Partners announces a further strengthening of its senior leadership with Ian Coyne joining the Managing Partners group. In addition to this strategic leadership expansion, the firm further refined the structure of its Senior Leadership team, with Joe Coulter assuming a new role as Chief Business Officer (CBO) and Charlotte James being promoted to Chief Operating Officer (COO). Ian Coyne, who joined Coulter Partners in 2019, is invited

Coulter Partners places R&D Senior Project Director at Vicore Pharma Holding

Coulter Partners successfully completed a search assignment for Vicore Pharma Holding AB (STO: VICO) and is pleased to announce the placement of Katrine Husum as R&D Senior Project Director. Vicore Pharma is a clinical-stage pharmaceutical company focused on developing treatments for severe respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company is developing a new class of drugs with